The new drug has already passed Phase 1 safety trials in humans, making it a "strong candidate" for future PTSD treatments.

Researchers discovered that PTSD may be driven by excess GABA from astrocytes, not neurons. This chemical imbalance disrupts ...

1. Monoamine Oxidase Inhibitors (MAOIs) Monoamine oxidase inhibitors (MAOIs) are a group of drugs that treat conditions like depression and Parkinson's disease, among others.

An experimental drug reverses PTSD-like symptoms in mice. The corresponding study was published in Signal Transduction and ...

Monoamine oxidase inhibitors are of two types: hydrazine derivatives, which inhibit both monoamine oxidase and diamine oxidase, the latter enzyme being important in the metabolism of histamine ...

The monoamine oxidase A (MAOA) gene is an outer membrane mitochondrial enzyme that breaks down monoamines such as serotonin, noradrenalin and dopamine. A common polymorphism in MAOA results in ...

Monoamine oxidase A (MAO A) degrades serotonin, norepinephrine, and dopamine and produces reactive oxygen that may cause neuronal cell death. We have previously reported that a novel transcription ...

Rasagiline: A Second-Generation Monoamine Oxidase Type-B Inhibitor for the Treatment of Parkinson's Disease Jack J. Chen; Anh-Vuong Ly Disclosures Am J Health Syst Pharm. 2006;63 (10):915-928.

Nicotine & Tobacco Research, Vol. 3, No. 4 (November 2001), pp. 383-390 (8 pages) Previous studies have found that constituents in tobacco inhibit both forms of the enzyme monoamine oxidase (MAO-A and ...